Biocon Biologics receives US $75 mn from ADQ; Valuation reaches US $4.17 Bn

Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.

Lonza posts CHF 6.5 billion in 2025 sales, marks strong profit growth

Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model

Moderna teams up with Recordati to commercialize rare disease therapy

Venus Remedies bags second PLI disbursement for FY25, nears full-year incentive

The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities

Sanofi’s Amlitelimab delivers in Phase 3 trials, heads for global filings

In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24

Eastman & Kolmar Korea join forces to deliver biodegradable beauty breakthroughs

The collaboration will center on expanding access to Eastman’s Esmeri technology

G Square acquires majority stake in Finnish surgical solutions leader Serres

Shionogi boosts stake in ViiV Healthcare in $2.125 billion deal, Pfizer exits

Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding

Zydus launches world’s first biosimilar of Nivolumab in India, cutting costs by 75%

AstraZeneca gains full global rights to AbelZeta’s CAR-T therapy in $630M deal